- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02142140
Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy of Careful Medication and Tailored Case Management Follow up Treatment for Children With Attention Deficit Hyperactivity Disorder
The purpose of the study is to examine how well two types of treatment follow up work compared to one another:
- standard community follow up
- medication monitoring plus tailored case management follow up.
A child's participation will involve 3 months of treatment consisting of medication and psychological, behavioural, and academic interventions tailored to their individual needs.
Following this treatment, the child will be randomly assigned to receive two years of either community follow up or medication monitoring plus tailored case management follow up delivered by the study team. During both types of follow up, at 6 month intervals, the parent and child will be asked to complete interviews with our study personnel and comprehensive assessments pertaining to ADHD symptoms and various other areas of functioning.
Parents will also be asked to obtain information from the child's teacher regarding the child's functioning at 6 month intervals during the school year.
Studieoversikt
Status
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, H4H 1R3
- Douglas Mental Health University Institute
-
Montreal, Quebec, Canada, H4A 3J1
- Montreal Children's Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- age 6 to 12 years
- DSM-IV ADHD diagnosis by a specialist i.e. child psychiatrist or developmental paediatrician (DSM 5 ADHD criteria do not differ dramatically from DSM IV criteria for children)
- Intelligence Quotient (IQ) > 80 as per the Wechsler Intelligence Scale for Children (WISC-IV)
- Proficiency in English or French
Exclusion Criteria:
- History of Autism Spectrum Disorder (ASD) or psychosis
- Significant brain traumas (encephalitis, head injury requiring hospitalization, etc.)
- Major medical conditions or impairments that would interfere with the ability of the child to complete testing or take psychostimulants, e.g., epilepsy, cardiac abnormalities, or renal abnormalities.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Medication Monitoring & Case Management
All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant).
Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training.
Participants randomized to this group will meet with the study clinicians 4 times a year for medication monitoring and adjustment.
This group will also receive a monthly call from a case manager who will explore the child's academic, social and emotional functioning.
Depending on the needs of the child and family, the case manager may offer 1 to 5 intervention sessions with the child (e.g.
social skills, anger management), the family (e.g.
family counselling), and the school (e.g.
consultation with the teacher).
|
This program aims at teaching children organization, time management and stress management skills.
They are also taught academic strategies in reading, writing, and math.
The program consists of six, 90 minute sessions.
The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively.
Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses.
Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective.
The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement.
The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable).
Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring.
In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
Andre navn:
The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable).
Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
Andre navn:
|
Aktiv komparator: Community Follow-up Group
All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant).
Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training.
Families randomized to this group will be referred to their pediatricians or family physicians for medication follow-up and their local Community Health Clinic (CLSC) for other psychosocial interventions that may be required and available.
|
This program aims at teaching children organization, time management and stress management skills.
They are also taught academic strategies in reading, writing, and math.
The program consists of six, 90 minute sessions.
The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively.
Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses.
Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective.
The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement.
The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable).
Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring.
In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
Andre navn:
The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable).
Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Attention Deficit Hyperactivity Disorder (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)
Tidsramme: At baseline - no medication
|
At baseline - no medication
|
Attention Deficit Hyperactivity Disorder (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)
Tidsramme: Following 3 months of tailored treatment (including medication)
|
Following 3 months of tailored treatment (including medication)
|
Attention Deficit Hyperactivity Disorder (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)
Tidsramme: Six months after tailored treatment ends - on medication
|
Six months after tailored treatment ends - on medication
|
Attention Deficit Hyperactivity Disorder (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)
Tidsramme: Twelve months after tailored treatment has ended - on medication
|
Twelve months after tailored treatment has ended - on medication
|
Attention Deficit Hyperactivity Disorder (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)
Tidsramme: Eighteen months after tailored treatment has ended - on medication
|
Eighteen months after tailored treatment has ended - on medication
|
Attention Deficit Hyperactivity Disorder (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)
Tidsramme: Twenty-four months after tailored treatment has ended - on medication
|
Twenty-four months after tailored treatment has ended - on medication
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Social skills (measured via Parent and Teacher Social Skills Rating Scale)
Tidsramme: At baseline - no medication
|
At baseline - no medication
|
|
Academic achievement (measured via Wechsler Individual Achievement Test (WIAT))
Tidsramme: At baseline - no medication
|
At baseline - no medication
|
|
Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))
Tidsramme: At baseline - no medication
|
At baseline - no medication
|
|
Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))
Tidsramme: At baseline - no medication
|
At baseline - no medication
|
|
Overall functioning (measured via the Clinical Global Impression Scale (CGI))
Tidsramme: Assessed at baseline
|
Assessed at baseline
|
|
Social skills (measured via Parent and Teacher Social Skills Rating Scale)
Tidsramme: Following 3 months of tailored treatment (including medication)
|
Following 3 months of tailored treatment (including medication)
|
|
Social skills (measured via Parent and Teacher Social Skills Rating Scale)
Tidsramme: Six months after tailored treatment ends - on medication
|
Six months after tailored treatment ends - on medication
|
|
Social skills (measured via Parent and Teacher Social Skills Rating Scale)
Tidsramme: Twelve months after tailored treatment has ended - on medication
|
Twelve months after tailored treatment has ended - on medication
|
|
Social skills (measured via Parent and Teacher Social Skills Rating Scale)
Tidsramme: Eighteen months after tailored treatment has ended - on medication
|
Eighteen months after tailored treatment has ended - on medication
|
|
Social skills (measured via Parent and Teacher Social Skills Rating Scale)
Tidsramme: Twenty-four months after tailored treatment has ended - on medication
|
Twenty-four months after tailored treatment has ended - on medication
|
|
Academic achievement (measured via Wechsler Individual Achievement Test (WIAT))
Tidsramme: Twelve month after tailored treatment has ended - on medication
|
Twelve month after tailored treatment has ended - on medication
|
|
Academic achievement (measured via Wechsler Individual Achievement Test (WIAT))
Tidsramme: Twenty-four months after tailored treatment has ended
|
Twenty-four months after tailored treatment has ended
|
|
Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))
Tidsramme: Following 3 months of tailored treatment (including medication)
|
Following 3 months of tailored treatment (including medication)
|
|
Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))
Tidsramme: Six months after tailored treatment ends - on medication
|
Six months after tailored treatment ends - on medication
|
|
Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))
Tidsramme: Twelve months after tailored treatment has ended - on medication
|
Twelve months after tailored treatment has ended - on medication
|
|
Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))
Tidsramme: Eighteen months after tailored treatment has ended - on medication
|
Eighteen months after tailored treatment has ended - on medication
|
|
Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))
Tidsramme: Twenty-four months after tailored treatment has ended - on medication
|
Twenty-four months after tailored treatment has ended - on medication
|
|
Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))
Tidsramme: Following 3 months of tailored treatment (including medication)
|
Following 3 months of tailored treatment (including medication)
|
|
Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))
Tidsramme: Six months after tailored treatment ends - on medication
|
Six months after tailored treatment ends - on medication
|
|
Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))
Tidsramme: Twelve months after tailored treatment has ended - on medication
|
Twelve months after tailored treatment has ended - on medication
|
|
Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))
Tidsramme: Eighteen months after tailored treatment has ended - on medication
|
Eighteen months after tailored treatment has ended - on medication
|
|
Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))
Tidsramme: Twenty-four months after tailored treatment has ended - on medication
|
Twenty-four months after tailored treatment has ended - on medication
|
|
Overall functioning (measured via the Clinical Global Impression Scale (CGI))
Tidsramme: Following 3 months of tailored treatment (including medication)
|
Following 3 months of tailored treatment (including medication)
|
|
Overall functioning (measured via the Clinical Global Impression Scale (CGI))
Tidsramme: Three months after tailored treatment ends - on medication
|
For participants randomized to the medication monitoring and tailored case management follow-up group.
|
Three months after tailored treatment ends - on medication
|
Overall functioning (measured via the Clinical Global Impression Scale (CGI))
Tidsramme: Six months after tailored treatment ends - on medication
|
For participants randomized to the medication monitoring and tailored case management follow-up group.
|
Six months after tailored treatment ends - on medication
|
Overall functioning (measured via the Clinical Global Impression Scale (CGI))
Tidsramme: Nine months after tailored treatment ends - on medication
|
For participants randomized to the medication monitoring and tailored case management follow-up group.
|
Nine months after tailored treatment ends - on medication
|
Overall functioning (measured via the Clinical Global Impression Scale (CGI))
Tidsramme: Twelve months after tailored treatment ends - on medication
|
For participants randomized to the medication monitoring and tailored case management follow-up group.
|
Twelve months after tailored treatment ends - on medication
|
Overall functioning (measured via the Clinical Global Impression Scale (CGI))
Tidsramme: Fifteen months after tailored treatment ends - on medication
|
For participants randomized to the medication monitoring and tailored case management follow-up group.
|
Fifteen months after tailored treatment ends - on medication
|
Overall functioning (measured via the Clinical Global Impression Scale (CGI))
Tidsramme: Eighteen months after tailored treatment ends - on medication
|
For participants randomized to the medication monitoring and tailored case management follow-up group.
|
Eighteen months after tailored treatment ends - on medication
|
Overall functioning (measured via the Clinical Global Impression Scale (CGI))
Tidsramme: Twenty-one months after tailored treatment ends - on medication
|
For participants randomized to the medication monitoring and tailored case management follow-up group.
|
Twenty-one months after tailored treatment ends - on medication
|
Overall functioning (measured via the Clinical Global Impression Scale (CGI))
Tidsramme: Twenty-four months after tailored treatment ends - on medication
|
For participants randomized to the medication monitoring and tailored case management follow-up group.
|
Twenty-four months after tailored treatment ends - on medication
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Ridha Joober, MD, PhD, Douglas Mental Health University Institute
- Hovedetterforsker: Natalie Grizenko, MD, FRCPC, Douglas Mental Health University Institute
- Hovedetterforsker: Lily Hechtman, MD, FRCPC, McGill University Health Centre/Research Institute of the McGill University Health Centre
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Psykiske lidelser
- Sykdommer i nervesystemet
- Nevrologiske manifestasjoner
- Dyskinesier
- Oppmerksomhetssvikt og forstyrrende atferdsforstyrrelser
- Nevroutviklingsforstyrrelser
- Attention Deficit Disorder med hyperaktivitet
- Hyperkinesi
- Fysiologiske effekter av legemidler
- Adrenerge midler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Nevrotransmitter opptakshemmere
- Membrantransportmodulatorer
- Dopaminmidler
- Dopaminopptakshemmere
- Adrenerge opptakshemmere
- Metylfenidat
- Lisdeksamfetamin Dimesylate
- Atomoksetinhydroklorid
- Dextroamfetamin
- Adderall
- Sentralnervesystemstimulerende midler
Andre studie-ID-numre
- MOP 123412
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Attention Deficit Hyperactivity Disorder (ADHD)
-
Children's National Research InstituteRekrutteringADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | LEGGE TIL | ADHD Overveiende uoppmerksom type | ADHD – kombinert type | ADHD, overveiende hyperaktiv - impulsiv | Oppmerksomhetsforstyrrelse i ungdomsårene | Attention-Deficit Hyperactivity...Forente stater
-
Ironshore Pharmaceuticals and Development, IncFullførtAttention-Deficit Hyperactivity Disorder (ADHD)Forente stater
-
Medical University of South CarolinaShireFullførtAdult Attention Deficit Hyperactivity Disorder (ADHD)Forente stater
-
Cingulate TherapeuticsRho, Inc.FullførtADHD | Attention Deficit Hyperactivity Disorder | ADHD – kombinert type | Attention Deficit Hyperactivity Disorder kombinertForente stater
-
Cingulate TherapeuticsPremier Research Group plcAktiv, ikke rekrutterendeADHD | Attention Deficit Hyperactivity Disorder | ADHD – kombinert type | Attention Deficit Hyperactivity Disorder kombinert | Hyperaktivitet med oppmerksomhetssvikt | Oppmerksomhetsunderskudd hyperaktivitetForente stater
-
Cingulate TherapeuticsRekrutteringADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder med hyperaktivitet | ADHD – kombinert type | Attention Deficit Hyperactivity Disorder kombinert | Hyperaktivitet med oppmerksomhetssvikt | Oppmerksomhetsunderskudd hyperaktivitetForente stater
-
Tris Pharma, Inc.Massachusetts General Hospital; Massachusetts Institute of TechnologyFullført
-
Karolinska InstitutetRegion StockholmFullført
-
AstraZenecaTargacept Inc.Fullført
-
University of CalgaryHar ikke rekruttert ennåAttention Deficit/ Hyperactivity Disorder (ADHD)Canada
Kliniske studier på Academic and Organization skills
-
Memorial Sloan Kettering Cancer CenterFullført
-
University Hospital, Basel, SwitzerlandNovartis; ProPatient foundation of the University Hospital BaselFullførtAplastisk anemi | Paroksysmal nattlig hemoglobinuriSveits
-
Wake Forest University Health SciencesFullførtGynekologisk kreft | Seksuell dysfunksjonForente stater
-
Hacettepe UniversityAnkara City Hospital BilkentFullført
-
H. Lee Moffitt Cancer Center and Research InstitutePfizerAktiv, ikke rekrutterendeNyrecellekarsinom stadium IVForente stater
-
Washington University School of MedicineVarian Medical SystemsFullførtIkke-småcellet lungekreft | Ikke-småcellet lungekreft | Karsinom, ikke-småcellet lungeForente stater
-
Groupe Hospitalier de la Region de Mulhouse et...Fullført
-
Washington University School of MedicineFullførtBrystkreft | Brystneoplasmer | Brystkreft | BrystkreftForente stater
-
H. Lee Moffitt Cancer Center and Research InstituteKite, A Gilead CompanyAktiv, ikke rekrutterendeDiffust storcellet B-celle lymfom | Transformert lymfomForente stater
-
Michigan State UniversityNational Institute of Nursing Research (NINR)FullførtBrystkreftForente stater